Evidence map›Paper›PMID 33291419›Full record

ArticleBiomolecules2020

Large Scale Conversion of Trilobolide into the Payload of Mipsagargin: 8-

Tomáš Zimmermann, Pavel Drašar, Silvie Rimpelová, Søren Brøgger Christensen, Vladimir A Khripach, Michal Jurášek

Abstract read
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Pharmacological Extracts and Molecules fromMolecules (Basel, Switzerland) · 2021
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tomáš ZimmermannDepartment of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic.ORCID 0000-0003-0529-723X
Pavel DrašarDepartment of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic.ORCID 0000-0003-0093-7007
Silvie RimpelováDepartment of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic.ORCID 0000-0002-3008-1396
Søren Brøgger ChristensenDepartment of Drug Design and Pharmacology, University of Copenhagen, Jagtvej 162, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-5773-6874
Vladimir A KhripachInstitute of Bioorganic Chemistry, National Academy of Sciences of Belarus, Kuprevich St. 5, 220141 Minsk, Belarus.
Michal JurášekDepartment of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic.ORCID 0000-0002-5069-9716

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In spite of the impressing cytotoxicity of thapsigargin (

Indexed as

Chemistry Techniques, SyntheticAntineoplastic Agents, PhytogenicApiaceaeButyratesCarbon DioxideChromatography, Supercritical FluidFruitFuransHumansMolecular StructureNeoplasmsPlant ExtractsSarcoplasmic Reticulum Calcium-Transporting ATPasesThapsigarginAntineoplastic Agents, PhytogenicButyratesCarbon DioxideFuransPlant ExtractsSarcoplasmic Reticulum Calcium-Transporting ATPasesThapsigargintrilobolide8-O-(12-aminododecanoyl)-8-O-debutanoylthapsigarginchemical synthesisextractionLaser trilobum cultivationmipsagarginoptimization and scale-upsarco/endoplasmic reticulum calcium ATPase (SERCA)sesquiterpene lactonesthapsigargintrilobolidetrilobolide isolation from fruits

Identifiers

PMID33291419
PMCPMC7762042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.